L
Laura B. L. Wittemans
Researcher at University of Cambridge
Publications - 25
Citations - 810
Laura B. L. Wittemans is an academic researcher from University of Cambridge. The author has contributed to research in topics: Gene & Biology. The author has an hindex of 9, co-authored 18 publications receiving 354 citations. Previous affiliations of Laura B. L. Wittemans include University of Oxford & Medical Research Council.
Papers
More filters
Journal ArticleDOI
Using human genetics to understand the disease impacts of testosterone in men and women
Katherine S. Ruth,Felix R. Day,Jessica Tyrrell,Deborah J. Thompson,Andrew R. Wood,Anubha Mahajan,Robin N Beaumont,Laura B. L. Wittemans,Laura B. L. Wittemans,Susan Martin,Alexander S Busch,Alexander S Busch,A. Mesut Erzurumluoglu,Benjamin Hollis,Tracy A. O'Mara,Mark I. McCarthy,Claudia Langenberg,Douglas F. Easton,Nicholas J. Wareham,Stephen Burgess,Anna Murray,Ken K. Ong,Ken K. Ong,Timothy M. Frayling,John R. B. Perry +24 more
TL;DR: Genetic analysis of data from over 400,000 participants in the UK Biobank Study shows that circulating testosterone levels have sex-specific implications for cardiometabolic diseases and cancer outcomes and the genetic determinants of testosterone levels are substantially different between sexes.
Journal ArticleDOI
Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors.
Luca A. Lotta,Laura B. L. Wittemans,Verena Zuber,Isobel D. Stewart,Stephen J. Sharp,Jian'an Luan,Felix R. Day,Chen Li,Nicholas Bowker,Lina Cai,Emanuella De Lucia Rolfe,Kay-Tee Khaw,John R. B. Perry,Stephen O'Rahilly,Robert A. Scott,David B. Savage,Stephen Burgess,Nicholas J. Wareham,Claudia Langenberg +18 more
TL;DR: Distinct genetic mechanisms may be linked to gluteofemoral and abdominal fat distribution that are the basis for the calculation of the WHR and may improve risk assessment and treatment of diabetes and coronary disease.
Journal ArticleDOI
A cross-platform approach identifies genetic regulators of human metabolism and health.
Luca A. Lotta,Maik Pietzner,Isobel D. Stewart,Laura B. L. Wittemans,Laura B. L. Wittemans,Chen Li,Roberto Bonelli,Roberto Bonelli,Johannes Raffler,Emma K. Biggs,Clare Oliver-Williams,Clare Oliver-Williams,Victoria P W Auyeung,Jian'an Luan,Eleanor Wheeler,Ellie Paige,Praveen Surendran,Gregory A. Michelotti,Robert A. Scott,Stephen Burgess,Verena Zuber,Verena Zuber,Eleanor Sanderson,Albert Koulman,Fumiaki Imamura,Nita G. Forouhi,Kay-Tee Khaw,Julian L. Griffin,Angela M. Wood,Gabi Kastenmüller,John Danesh,Adam S. Butterworth,Fiona M. Gribble,Frank Reimann,Melanie Bahlo,Melanie Bahlo,Eric B. Fauman,Nicholas J. Wareham,Claudia Langenberg,Claudia Langenberg +39 more
TL;DR: In this paper, the authors identify a signal at GLP2R (p.Asp470Asn) shared among higher citrulline levels, body mass index, fasting glucose-dependent insulinotropic peptide and type 2 diabetes, with β-arrestin signaling as the underlying mechanism.
Journal ArticleDOI
Assessing the causal association of glycine with risk of cardio-metabolic diseases
Laura B. L. Wittemans,Luca A. Lotta,Clare Oliver-Williams,Isobel D. Stewart,Praveen Surendran,Savita Karthikeyan,Felix R. Day,Albert Koulman,Fumiaki Imamura,Lingyao Zeng,Jeanette Erdmann,Heribert Schunkert,Kay-Tee Khaw,Julian L. Griffin,Nita G. Forouhi,Robert A. Scott,Angela M. Wood,Stephen Burgess,Joanna M. M. Howson,John Danesh,John Danesh,Nicholas J. Wareham,Adam S. Butterworth,Claudia Langenberg +23 more
TL;DR: It is shown that glycine is genetically associated with lower CHD risk and found that this may be partly driven by blood pressure, and a strong inverse genetic effect of hyperinsulinaemia on glycine, which strengthens evidence for a protective effect of glycine on CHD.
Journal ArticleDOI
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Luca A. Lotta,Isobel D. Stewart,Stephen J. Sharp,Felix R. Day,Stephen Burgess,Jian'an Luan,Nicholas Bowker,Lina Cai,Chen Li,Laura B. L. Wittemans,Nicola D. Kerrison,Kay-Tee Khaw,Mark I. McCarthy,Mark I. McCarthy,Stephen O'Rahilly,Robert A. Scott,David B. Savage,John R. B. Perry,Claudia Langenberg,Nicholas J. Wareham +19 more
TL;DR: Human genetics evidence is provided to support the development of agents that enhance LPL-mediated lipolysis for further clinical benefit in addition to LDL-C–lowering therapy and triglyceride-lowering alleles in the LPL pathway are associated with lower risk of coronary disease and type 2 diabetes.